Amneal Pharmaceuticals Inc
NYSE:AMRX
Amneal Pharmaceuticals Inc
NYSE:AMRX
Price:
6.87 USD
0.29%
Market Closed
Updated:
May 16, 2024
Amneal Pharmaceuticals Inc
Income from Continuing Operations
|
Amneal Pharmaceuticals Inc
Income from Continuing Operations Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Amneal Pharmaceuticals Inc
NYSE:AMRX
|
Income from Continuing Operations
-$48.7m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Income from Continuing Operations
$17.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Income from Continuing Operations
-$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
Income from Continuing Operations
-$254m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Income from Continuing Operations
$2.3B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Income from Continuing Operations
$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
18%
|
CAGR 10-Years
5%
|
See Also
What is Amneal Pharmaceuticals Inc's Income from Continuing Operations?
Income from Continuing Operations
-48.7m
USD
-48.7m
USD
Based on the financial report for Dec 31, 2023, Amneal Pharmaceuticals Inc's Income from Continuing Operations amounts to -48.7m USD.
What is Amneal Pharmaceuticals Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
25%
25%
Over the last year, the Income from Continuing Operations growth was 81%. The average annual Income from Continuing Operations growth rates for Amneal Pharmaceuticals Inc have been -6% over the past three years , 25% over the past five years .
You don't have any saved screeners yet
